STRATEC Biomedical AG (SBSG.DE) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Edison Investment Research
$10.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Stratec Biomedical AG confirms FY 2014 outlook and confirms medium-term financial forecast for years through to 2017


Wednesday, 23 Jul 2014 01:35am EDT 

Stratec Biomedical AG:Continues to expect for FY 2014 substantial sales growth compared with FY 2013 financial, accompanied by slight increase in EBIT margin.Says medium-term financial forecast for years through to 2017 provides for average annual sales growth of 8 pct to 12 pct based on volume of sales generated in FY 2013. 

Company Quote

52.41
0.42 +0.81%
7:25am EDT